PLEASANTON, Calif., April 17, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that as of April 2012, clinicians have implanted more than 10,000 HeartMate II® Left Ventricular Assist Devices (LVADs) in patients suffering from advanced heart failure (AHF) worldwide.
The HeartMate II is a small implantable mechanical device that helps circulate blood throughout the body. Sometimes called a "heart pump" or "VAD," it is designed to supplement the pumping function of the heart for patients whose hearts are too weak to pump blood adequately on their own.
"Every year, millions of people worldwide develop chronic heart failure, and many will progress to an advanced, debilitating stage of the disease," said Gary Burbach, President and Chief Executive Officer of Thoratec. "Today, we recognize the more than 10,000 individuals who have been implanted with HeartMate II – the device that is setting the standard for proven, long-term support of advanced heart failure patients. I want to congratulate and thank everyone involved for contributing to this milestone event. This is a great achievement for the medical community and, most importantly, for the patients who have benefited from this life-restoring treatment option."
HeartMate II has been extensively studied, both in clinical trials and in commercial, real-world experience, and has been approved by the U.S. Food and Drug Administration (FDA) as well as international regulatory bodies to support advanced heart failure patients. For individuals with AHF, the heart has difficulty pumping blood and is unable to supply the body with adequate levels of oxygen. As a result, AHF patients feel tired or weak, even when doing simple things, like walking or eating. The use of an LVAD, such as the HeartMate II, is considered an appropriate treatment option in cases of AHF. Studies have shown that patients treated with an LVAD can live longer and enjoy a much-improved quality of life compared with those being treated with drug therapy alone.,
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV